BlackRock Fund Advisors’s Travere Therapeutics TVTX Stock Holding History

BlackRock Fund Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$30.9M	Buy	1,631,894 +216,676	+15%	+$4.43M	0.01%	1953
2016 Q3	$31.7M	Buy	1,415,218 +89,272	+7%	+$1.7M	0.01%	1851
2016 Q2	$23.6M	Buy	1,325,946 +22,957	+2%	+$372K	0.01%	1941
2016 Q1	$17.8M	Buy	1,302,989 +22,903	+2%	+$347K	﹤0.01%	2053
2015 Q4	$24.7M	Sell	1,280,086 -63,186	-5%	-$1.26M	0.01%	1911
2015 Q3	$27.2M	Buy	1,343,272 +56,070	+4%	+$1.66M	0.01%	1802
2015 Q2	$42.7M	Buy	1,287,202 +195,218	+18%	+$5.35M	0.01%	1629
2015 Q1	$26.2M	Buy	1,091,984 +180,530	+20%	+$2.75M	0.01%	1930
2014 Q4	$11.2M	Buy	911,454 +394,999	+76%	+$4.09M	﹤0.01%	2398
2014 Q3	$4.66M	Sell	516,455 -7,888	-2%	-$92.8K	﹤0.01%	2796
2014 Q2	$6.16M	Sell	524,343 -2,990	-0.6%	-$40.5K	﹤0.01%	2719
2014 Q1	$11.2M	Buy	+527,333	New	+$8.11M	﹤0.01%	2335

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock Fund Advisors's TVTX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Travere Therapeutics (TVTX) stake by 15% in Q4 2016, buying an estimated $4.43M and bringing the position to 1,631,894 shares worth $30.9M. The position accounts for 0.01% of the portfolio, ranked #1953.

BlackRock Fund Advisors first reported a position in TVTX in Q1 2014 and has held it in 12 quarters since. The position peaked at $42.7M in Q2 2015. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

BlackRock Fund Advisors held 1,631,894 shares of Travere Therapeutics worth $30.9M as of Q4 2016.
BlackRock Fund Advisors bought 216,676 Travere Therapeutics shares in Q4 2016, an estimated $4.43M.
Travere Therapeutics made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1953 holding.
BlackRock Fund Advisors first reported a position in Travere Therapeutics in Q1 2014 and has held it in 12 quarters since.
BlackRock Fund Advisors's Travere Therapeutics position peaked at $42.7M in Q2 2015.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.